Although some studies have proposed the potential utility of tumour location (specifically, the body and tail of the pancreas), CEA levels [64], and clinical symptoms such as weight loss and jaundice, the existing evidence is insufficient to warrant their inclusion in a selection algorithm. The gene discussed is CEACAM5; the disease is neoplasm.